Validation of a New Transcutaneous tcPO2/tcPCO2 Sensor with an Optical Oxygen Measurement in Preterm Neonates

Willem van Weteringen y cols. Neonatology 2020;117:628–636

Resumen

Introducción:

Las mediciones tradicionales de O2 transcutáneo se ven afectadas por el desvío de la medición, lo que impacta en la precisión y usabilidad. La nueva técnica de exención de fluorescencia potencialmente libre del desvío del oxígeno se ha combinado con el uso de un sensor único para monitoreo de dióxido de carbono transcutáneo convencional (tcPCO2). Este estudio tuvo como objetivo validar tcPO2 óptica y tcPCO2 convencional versus gases en muestras de sangre arterial en recién nacidos prematuros y determinar la diferencia en la medición.

Métodos: En este estudio observacional prospectivo, durante atención regular, se compararon las mediciones transcutáneas versus la de los gases en sangre arterial de recién nacidos prematuros de 24 a 31 semanas de edad gestacional (EG) extraída de catéter arterial. Las muestras fueron incluidas en base a criterios de estabilidad y estratificados según el estado de sepsis. La concordancia se evaluó utilizando Análisis de Altman. Se calculó la deriva de medición por hora.

Resultados: Se incluyeron 68 recién nacidos prematuros {mediana (rango intercuartílico [IQR]) EG de 26 4/7 [25 3/7–27 5/7] semanas}, resultando en 216 muestras pareadas estables. Las muestras resultaron estables en neonatos sin sepsis (n = 38) y con sospecha de sepsis (n = 112) fueron aceptable para tcPO2 y buenas para tcPCO2. Sin embargo, en muestras estables de neonatos con sepsis (n = 66), la concordancia de tcPO2 (sesgo y límites del 95% de acuerdo) fue -32,6 (-97,0 a 31,8) mm Hg y tcPCO2 el acuerdo fue de 4,2 (-10,5 a 18,9) mm Hg. En la mediana (IQR) los valores absolutos de la deriva fueron 0.058 (0.0231-0.1013) mm Hg / h para tcPO2 y 0,30 (0,11–0,64) mm Hg / h para tcPCO2. Conclusión:

La precisión del tcPO2 óptico en neonatos prematuros
fue aceptable sin sepsis, mientras que electroquímicamente
La tcPCO2 medida se mantuvo precisa en todas las circunstancias.
La deriva de la medición fue insignificante para tcPO2 y
aceptable para tcPCO2.
Validation of a New Transcutaneous tcPO\textsubscript{2}/tcPCO\textsubscript{2} Sensor with an Optical Oxygen Measurement in Preterm Neonates

Willem van Weteringen\textsuperscript{a,b} Tanja van Essen\textsuperscript{b} Norani H. Gangaram-Panday\textsuperscript{b} Tom G. Goos\textsuperscript{b,c} Rogier C.J. de Jonge\textsuperscript{d} Irwin K.M. Reiss\textsuperscript{b}

\textsuperscript{a}Department of Pediatric Surgery, Erasmus MC – Sophia Children’s Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands; \textsuperscript{b}Department of Pediatrics, Division of Neonatology, Erasmus MC – Sophia Children’s Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands; \textsuperscript{c}Department of Biomechanical Engineering, Faculty of Mechanical Engineering, Delft University of Technology, Delft, The Netherlands; \textsuperscript{d}Pediatric Intensive Care Unit, Departments of Pediatrics and Pediatric Surgery, Erasmus MC – Sophia Children’s Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands

Keywords
Transcutaneous measurements · Transcutaneous oxygen · Transcutaneous carbon dioxide · Sensor · Neonate

Abstract

Introduction: Traditional transcutaneous oxygen (tcPO\textsubscript{2}) measurements are affected by measurement drift, limiting accuracy and usability. The new potentially drift-free oxygen fluorescence quenching technique has been combined in a single sensor with conventional transcutaneous carbon dioxide (tcPCO\textsubscript{2}) monitoring. This study aimed to validate optical tcPO\textsubscript{2} and conventional tcPCO\textsubscript{2} against arterial blood gas samples in preterm neonates and determine measurement drift.

Methods: In this prospective observational study, during regular care, transcutaneous measurements were paired to arterial blood gases from preterm neonates aged 24–31 weeks of gestational age (GA) with an arterial catheter. Samples were included based on stability criteria and stratified for sepsis status. Agreement was assessed using the Bland-Altman analysis. Measurement drift per hour was calculated.

Results: Sixty-eight premature neonates were included (median (interquartile range [IQR]) GA of 26 4/7 [25 3/7–27 5/7] weeks), resulting in 216 stable paired samples. Agreement of stable samples in neonates without sepsis (n = 38) and with suspected sepsis (n = 112) was acceptable for tcPO\textsubscript{2} and good for tcPCO\textsubscript{2}. However, in stable samples of neonates with sepsis (n = 66), tcPO\textsubscript{2} agreement (bias and 95% limits of agreement) was −32.6 (−97.0 to 31.8) mm Hg and tcPCO\textsubscript{2} agreement was 4.2 (−10.5 to 18.9) mm Hg. The median (IQR) absolute drift values were 0.058 (0.023–0.101) mm Hg/h for tcPO\textsubscript{2} and 0.30 (0.11–0.64) mm Hg/h for tcPCO\textsubscript{2}.

Conclusion: The accuracy of optical tcPO\textsubscript{2} in premature neonates was acceptable without sepsis, while electrochemically measured tcPCO\textsubscript{2} remained accurate under all circumstances. Measurement drift was negligible for tcPO\textsubscript{2} and highly acceptable for tcPCO\textsubscript{2}.

© 2020 The Author(s)
Published by S. Karger AG, Basel

Introduction

Transcutaneous blood gas monitoring is widely used in neonatal intensive care [1, 2]. It provides a continuous, noninvasive alternative to arterial blood gas sampling for...
measuring oxygen and carbon dioxide levels. The skin is arterialized by locally applying heat, causing an increase in microcirculatory blood flow. As a consequence, arterial values of oxygen and carbon dioxide can be estimated from values measured at the skin surface [3,4]. The agreement of transcutaneously measured blood gas values with arterial values is, however, affected by factors that influence skin gas diffusion [5–7]. The diffusion capacity of the skin for oxygen is markedly lower than that for carbon dioxide and decreases with age, allowing transcutaneous oxygen (tcPO\(_2\)) levels to reach arterial levels only in thin neonatal skin [8–10]. Until now, transcutaneous blood gas measurement techniques have been based on an electrochemical measurement principle [11,12]. Binding of other substances to the electrodes causes measurement drift over time, leading to additional inaccuracy [13]. While transcutaneous carbon dioxide (tcPCO\(_2\)) measurements are generally considered clinically useable, oxygen measurements suffer from inherent electrode instability and the fact that the electrochemical Clark-type electrode consumes oxygen, resulting in the underestimation of oxygen levels [14]. The main reasons for the sparse use of tcPO\(_2\) monitoring are the labor intensity of frequent sensor repositioning and poor measurement accuracy. In previous studies, the large variation in patient populations, applied sensor temperatures, and mixed inclusion of capillary and arterial samples have led to a large spread in, often contradicting, study results [15]. Recently, a new transcutaneous sensor has been introduced, featuring an optical fluorescence quenching oxygen measurement, combined with a conventional electrochemical carbon dioxide sensor [16]. The fluorescence quenching technique measures oxygen levels through fluorescence decay of a dye that is quenched by oxygen, resulting in reduced fluorescence intensity and decay rates [17]. This study aimed to validate this new combined transcutaneous sensor in premature neonates, by assessing agreement with arterial blood gas samples and determining drift, while ensuring accurate comparison by applying criteria for measurement stability.

Materials and Methods

Study Set-Up

A prospective observational study was performed at a level III neonatal intensive care unit in the Netherlands. Neonates of 24 0/7 up to and including 31 6/7 weeks of gestational age (GA) with an arterial catheter were included upon the clinical indication for standard of care transcutaneous blood gas monitoring.

Transcutaneous Devices

Patients were provided with a SenTec OxiVen\(^{TM}\) Sensor (SenTec AG, Therwil, Switzerland) and a SenTec SDM-PO2 (SenTec Digital Monitor) for a minimum of 48 h or until the clinical indication ended. Sensor temperatures were set according to the department protocol: 42.0°C for extreme preterm neonates (≤25 weeks of GA) and 43.0°C for preterm neonates (26–31 weeks of GA). The site time and safety features were set to 2 h for extreme preterm neonates and 3 h for preterm neonates, automatically lowering the sensor temperature to 39°C after the measurement time elapsed. Calibration of the tcPCO\(_2\) measurement was automatically required after the site time elapsed, the tcPO\(_2\) measurement was calibrated automatically approximately every 24 h during a tcPCO\(_2\) calibration. The SpO\(_2\) channel was disabled in the neonatal mode of the transcutaneous monitor. Sensor membranes were changed every 30 days or earlier in case of any visible damage or recurrent calibration errors. Skin fixation adhesives and contact gel were used in accordance with manufacturer guidelines.

Parameters and Data Acquisition

TcPO\(_2\) and tcPCO\(_2\) measurements, quality indicators, sensor temperature, and calibration information were logged (Raspberry Pi 2 or 3 model B, Raspberry Pi Foundation, UK) at a 1 Hz rate. Arterial pressures were logged at a 1 Hz rate from the patient monitoring system (Dräger M540, Drägerwerk AG & Co., KGaA, Lübeck, Germany). Arterial blood samples were analyzed with a Radiometer ABL800 FLEX (Radiometer, Copenhagen, Denmark). Patient characteristics and arterial blood sample data were retrieved from the hospital patient information system (PDMS, Picis Clinical Solutions, Wakefield, MA, USA). The number of days between birth and the moment of blood sampling was presented as an indicator of development of the skin on the measurements. Ventilation parameters, infection laboratory parameters, and blood culture results were additionally documented.

Sample Selection

Arterial Sampling

Arterial pressure data were used to verify the arterial origin of the blood samples. For blood sampling, the connection between the arterial line and the pressure transducer was temporarily closed. The heparin lock was removed, a blood sample was taken, and the heparin lock was flushed. A clear pressure change could be observed for each of these steps, which was used to match the exact moment of blood sampling with the corresponding transcutaneous measurements (Fig. 1).

Sensor Temperature

Data pairs were excluded when blood sampling during standard care coincided with an elapsed transcutaneous measurement time.

Measurement Stability

Measurement stabilization and respiratory dynamics often lead to fluctuations in transcutaneous measurements. To guarantee a proper comparison between transcutaneous and arterial blood gas values, measurement stability criteria were applied to each sample. A parameter indicating the stability status was provided by the monitor. Additionally, around the exact moment of blood sampling, a time window of 10 min was analyzed for transcutaneous measurement stability (Fig. 1). The sample was marked

DOI: 10.1159/000510659
as unstable (Fig. 1d) when either tcPO₂ or tcPCO₂ data were missing from this time interval, or a relative deviation of more than 3.75 mm Hg was present in the tcPO₂ and/or tcPCO₂ values (Fig. 1c).

Sepsis Definition
The neonate’s sepsis status was defined for each data pair to indicate the influence on skin microcirculation and potential blood gas diffusion (Fig. 2b).

Analyses
Demographics
Demographic data were reported as median and interquartile range (IQR) or as n (%). To study significance between patient groups in the subgroup analyses, the Kruskal-Wallis and Fisher’s exact tests were used for continuous and categorical variables, respectively. The significance level of statistical tests was fixed at α = 0.05.

Agreement and Correlation
Agreement between transcutaneous measurements and arterial blood gas samples was calculated according to Bland and Altman (A-B plot), accounting for multiple measurements per patient

Drift
The drift per hour of tcPO₂ and tcPCO₂ was calculated for each data pair by subtracting the calibration values after and before blood sampling. Duplicate calibration values originating from multiple data pairs within 1 calibration interval were removed. Drift is presented as median (IQR) for tcPO₂ and tcPCO₂, shown as absolute values due to the possibility of either positive or negative drift values.

Software
Statistical analyses were performed in R v3.5.3 (The R Foundation for Statistical Computing, Vienna, Austria). A sample selection program was built in LabVIEW (National Instruments, Austin, TX, USA).
**Table 1.** Patient and sample characteristics of included premature neonates and data pairs

| Variable                        | Value                              |
|---------------------------------|------------------------------------|
| GA at birth, weeks              | 26 4/7 (25 3/7–27 5/7)             |
| Birth weight, g                 | 803 (708–1,006)                    |
| Gender, male                    | 45 (66.2)                          |
| Delivery mode                   |                                    |
| Cesarean section                | 48 (70.6)                          |
| Vaginal                         | 20 (29.4)                          |
| Apgar                           |                                    |
| At min 1                        | 5 (3–7)                            |
| At min 5                        | 8 (6–9)                            |
| At min 10                       | 9 (8–9)                            |
| Umbilical cord pH               | 7.31 (7.25–7.34)                   |
| Multiple births                 | 11 (16.2)                          |
| Sepsis during admission         | 42 (61.8)                          |
| Deceased during admission       | 27 (39.7)                          |
| Samples per patient             | 9 (4–13)                           |
| GA at sample, weeks             | 27 6/7 (26 5/7–29 4/7)             |
| Days since birth                | 6 (3–12)                           |
| Weight at sampling, g           | 880 (680–1,195)                    |
| Ventilation mode                |                                    |
| Noninvasive ventilation         | 3 (0.5)                            |
| Invasive ventilation            | 288 (46.1)                         |
| High-frequency oscillatory vent  | 334 (53.4)                         |
| Sensor temperature, °C          |                                    |
| 42                              | 113 (18.1)                         |
| 43                              | 512 (81.9)                         |
| PaO<sub>2</sub>, mm Hg          | 57.8 (48.8–68.3)                   |
| PaCO<sub>2</sub>, mm Hg         | 48.0 (41.3–54.0)                   |

Values are expressed as median (IQR) or n (%), unless otherwise indicated. GA, gestational age; IQR, interquartile range.

**Results**

**Patient Demographics**

Between November 2015 and April 2017, 68 premature neonates were included out of a total number of 380 neonatal intensive care unit admittances aged 26–31 weeks of GA. Neonates had a median GA of 26 4/7 (IQR 25 3/7–27 5/7) weeks at birth and a median birth weight of 803 (IQR 708–1,006) g (Table 1). In the study population, the incidence of sepsis was considerably higher (61.8%) than the incidence in all admitted neonates with a GA of 26–31 weeks (22.1%) during the inclusion period. Of the 42 neonates with proven sepsis, there was only 1 case of early-onset sepsis.

**Sample Characteristics**

A total of 625 data pairs of arterial blood gas and transcutaneous measurements were collected and analyzed (Fig. 2a; Table 1), with a median sampled PaO<sub>2</sub> of 57.8 (IQR 48.8–68.3) mm Hg and PaCO<sub>2</sub> of 48.0 (IQR 41.3–54.0) mm Hg. No burns or skin irritation was observed in any of the neonates. The transcutaneous sensor was placed mostly at the thorax, abdomen, and lower extremity.

**Sample Stability**

The stability criteria were met by 216 (34.6%) data pairs. The Bland-Altman analysis showed a bias of tcPO<sub>2</sub> and PaO<sub>2</sub> data pairs of −19.1 (95% LoA −64.6 to 26.5) mm Hg (Pearson’s r = 0.37) and a tcPCO<sub>2</sub> and PaCO<sub>2</sub> bias of 4.7 (95% LoA −7.8 to 17.1) mm Hg (Pearson’s r = 0.85).

**Subgroup and Sepsis Status Analysis**

The effects of GA at birth, age of the skin, weight at the moment of blood sampling, sepsis status, and sensor temperature are shown in Table 2. Neonates in the sepsis group were older (GA: no sepsis 28 3/7 [26 4/7–29 6/7] weeks, suspected sepsis 27 6/7 [26 6/7–30 5/7] weeks, and sepsis 29 3/7 [27 6/7–31 3/7] weeks, p = 0.001) and had a higher weight (no sepsis 912 [622–1,260] g, suspected sepsis 930 [714–1,295] g, and sepsis 1,115 [839–1,690] g, p = 0.002) at the moment of blood gas sampling than the other groups, while this discrepancy was not present at birth. The Bland-Altman analysis of tcPO<sub>2</sub> and PaO<sub>2</sub> showed wide LoA for the sepsis group (Fig. 3). Agreement improved markedly for samples classified as suspected sepsis and no sepsis. In contrast, agreement of tcPCO<sub>2</sub> with PaCO<sub>2</sub> was minimally influenced by the sepsis status of the neonate.

**Measurement Drift**

Measurement drift was calculated for all unique calibrations of tcPO<sub>2</sub> (n = 327) and tcPCO<sub>2</sub> (n = 573). TcPO<sub>2</sub> drift was minimal, with a median (IQR) absolute drift of 0.058 (0.0231–0.1013) mm Hg/h, while tcPCO<sub>2</sub> drift was on par with the existing literature on tcPCO<sub>2</sub> sensors (median [IQR] drift of 0.30 [0.11–0.64] mm Hg/h) [19, 20].

**Discussion**

In this study, a new transcutaneous blood gas sensor using an optical technique for measuring oxygen was evaluated in a premature neonatal population during standard care. The primary outcome of this study is that...
Data pair selection

Included between November 2015 and April 2017
Patients $n = 68$
Data pairs $n = 645$
Unique calibration lines:
tcPCO$_2$ $n = 591$
tcPO$_2$ $n = 339$

Included for analysis
Patients $n = 68$
Data pairs $n = 625$
Unique calibration lines:
tcPCO$_2$ $n = 573$
tcPO$_2$ $n = 327$

After application of stability criteria
Patients $n = 57$
Data pairs $n = 216$

Stability selection – 10 min window
<10 min of stability information
Relative deviation of >3.75 mm Hg
Data pairs $n = 339$

Sensor temperature
Low sensor temperature due to elapsed measurement time
Data pairs $n = 20$
Unique calibration lines:
tcPCO$_2$ $n = 18$
tcPO$_2$ $n = 12$

Subgroup analysis

Sepsis status definition

Data pair timing relative to blood culture

Time window

5 days – 1 day before BC

BC pos/neg

CRP $\leq$ 10 mg/ml
Leukocytes $\geq$ 6 & $\leq$ 15 $\times 10^9$/l

No Sepsis

CRP $> 10$ mg/ml
Leukocytes $< 6$ or $> 15$ $\times 10^9$/l

Suspected Sepsis

CRP $\leq$ 10 mg/ml
Leukocytes $\geq 6$ & $\leq 15$ $\times 10^9$/l

Suspected Sepsis

CRP $> 10$ mg/ml
Leukocytes $< 6$ or $> 15$ $\times 10^9$/l

Sepsis

CRP $\leq$ 10 mg/ml
Leukocytes $\geq 6$ & $\leq 15$ $\times 10^9$/l

Suspected Sepsis

CRP $> 10$ mg/ml
Leukocytes $< 6$ or $> 15$ $\times 10^9$/l

Suspected Sepsis

CRP $\leq$ 10 mg/ml
Leukocytes $\geq 6$ & $\leq 15$ $\times 10^9$/l

No Sepsis

BC positive

BC negative

Outside BC time windows

Fig. 2. a Flowchart of inclusion and exclusion of patients, data pairs, and unique calibration lines. b Flowchart of sepsis status definition. BC, blood culture; AB, antibiotic; CRP, C-reactive protein; tcPO$_2$, transcutaneous oxygen; tcPCO$_2$, transcutaneous carbon dioxide.
agreement of stable tcPO₂ values with PaO₂ is acceptable in suspected septic and nonseptic patients, while overall agreement of tcPCO₂ with PaCO₂ remains excellent even with sepsis. The current literature on tcPO₂ sensors shows similar results in terms of agreement [21, 22]. Conventional tcPO₂ sensors however apply a correction factor for, among other influences, the oxygen consumption of the Clark-type electrode or the so-called stirring effect [3, 14]. The investigated sensor provides the actual skin oxygen level, leading to negative agreement when oxygen diffusion is impaired. Most interesting in this study was the factor of sepsis, which caused poor agreement between tcPO₂ and PaO₂, potentially due to impairment of the microcirculation [23]. In this study, the definition of sepsis was based on hospital guidelines and current literature [24]. In the sepsis group, the older age and consequent development of the neonatal skin may also influence the diffusion capacity of oxygen and thus the agreement of tcPO₂ with PaO₂. Whenever there is a lack of agreement of tcPO₂ with PaO₂, edema, impaired perfusion, or incorrect sensor placement should be considered.

Transcutaneous monitoring was mostly used to monitor CO₂ during high-frequency oscillatory ventilation, used as rescue therapy. This resulted in a high prevalence of, mostly late-onset, sepsis (61.8%) and mortality (39.7%) during admission in this study population. Unfortunately, during routine care, sensor skin locations were not registered, potentially influencing agreement due to skin microcirculation heterogeneity [14, 25]. The investigated sensor was provided with skin adhesives that performed well even under humid incubator conditions and allowed for sensor repositioning for kangaroo care.

The methodological aim of this study was to remove the cause of highly varying results on transcutaneous

### Table 2. Subgroup analysis of agreement

| Parameter                  | Samples, n | tcPO₂-PaO₂, mm Hg | tcPCO₂-PaCO₂, mm Hg |
|----------------------------|------------|--------------------|--------------------|
|                            |            | bias               | lower LoA-upper LoA | bias               | lower LoA-upper LoA | R    |
| GA at birth, weeks         |            |                    |                    |                    |                    |      |
| 24 0/7 to 25 6/7           | 60         | −18.6              | −48.3 to 11.0      | 0.21               | 4.3                | −9.6 to 18.2 | 0.76 |
| 26 0/7 to 27 6/7           | 94         | −16.5              | −58.1 to 25.2      | 0.36               | 4.9                | −4.5 to 14.2 | 0.91 |
| 28 0/7 to 29 6/7           | 17         | −19.8              | −55.3 to 15.8      | 0.38               | 2.5                | −4.9 to 9.9  | 0.95 |
| 30 0/7 to 31 6/7           | 45         | −24.7              | −95.6 to 46.1      | 0.49               | 5.5                | −12.0 to 22.9 | 0.80 |
| Postnatal skin age, week   |            |                    |                    |                    |                    |      |
| <1                        | 132        | −15.5              | −61.1 to 30.2      | 0.50               | 5.0                | −6.2 to 16.3 | 0.90 |
| ≥1                        | 84         | −24.7              | −68.4 to 19.0      | 0.22               | 4.0                | −10.3 to 18.4 | 0.78 |
| Weight at sampling, kg     |            |                    |                    |                    |                    |      |
| <1                        | 116        | −15.7              | −54.7 to 23.4      | 0.34               | 4.7                | −6.9 to 16.3 | 0.86 |
| ≥1                        | 100        | −23.0              | −74.6 to 28.6      | 0.41               | 4.6                | −9.0 to 18.1 | 0.84 |
| Sepsis status              |            |                    |                    |                    |                    |      |
| No sepsis                 | 38         | −16.1              | −49.7 to 17.6      | 0.11               | 3.4                | −3.9 to 10.7 | 0.95 |
| Suspected sepsis           | 112        | −12.1              | −36.9 to 12.7      | 0.55               | 5.3                | −7.1 to 17.8 | 0.87 |
| Sepsis                     | 66         | −32.6              | −97.0 to 31.8      | 0.45               | 4.2                | −10.5 to 18.9 | 0.70 |
| Sensor temperature, °C     |            |                    |                    |                    |                    |      |
| 42                        | 37         | −19.7              | −64.6 to 25.2      | −0.40              | 7.8                | −2.2 to 17.7 | 0.90 |
| 43                        | 179        | −18.9              | −64.6 to 26.8      | 0.45               | 4.0                | −8.6 to 16.6 | 0.84 |

Bias and 95% LoA in all stable samples related to GA at birth, age of the skin, weight at sampling, sepsis status, and sensor temperature. r represents Pearson’s correlation coefficient. LoA, limits of agreement; GA, gestational age; tcPO₂, transcutaneous oxygen; tcPCO₂, transcutaneous carbon dioxide.
monitoring in previous studies by improving the time-synchronized matching between transcutaneous measurements and arterial blood gas samples [15]. The inclusion and exclusion criteria for sample selection and measurement stability aim to improve reproducibility of future studies on transcutaneous monitoring. The criteria provide the possibility to distinguish the kinetics and dynamic properties of cardiorespiratory changes from those related to gas diffusion. The agreement analysis accounted for multiple measurements per patient, resulting in increased LoA when compared to other studies.

The investigated sensor provides a solution to the problem of tcPO₂ measurement drift, an inherent property of electrochemical blood gas sensors [13]. Although measurement drift is a well-known problem, few studies provide quantitative data that have been obtained during standard care. The conventional tcPCO₂ drift was comparable to previous studies [19, 20]. Improvements in transcutaneous measurement drift are able to significantly improve clinical usability, reliability, and accuracy. In the case of tcPO₂, this might even increase competition with pulse oximetry [26–28], providing trend informa-

Fig. 3. Bland-Altman plot of the measured tcPO₂ (a) and tcPCO₂ (b) against arterial blood gas values for the defined sepsis status of the neonates. tcPO₂, transcutaneous oxygen; tcPCO₂, transcutaneous carbon dioxide.
tion on reasonable estimates of the actual PaO$_2$ when calibrated to an arterial blood gas sample. The investigated sensor requires regular tcPCO$_2$ calibration, limiting the long-term accuracy advantage of the drift-free tcPO$_2$ measurement. A dedicated optical tcPO$_2$ sensor that would only need measures to prevent skin burns could provide a useful complement to neonatal oxygen monitoring.

Regardless of technical performance, the microcirculatory condition of the patient and optimal timing of blood sampling during a stable phase are of great influence on agreement of the measurements with arterial values. The influence of sepsis as demonstrated in this study is one of many potential patient-related factors that should be taken into account during the clinical use of transcutaneous monitoring.

**Conclusion**

The investigated combined optical tcPO$_2$ and conventional tcPCO$_2$ sensor provided acceptable agreement of tcPO$_2$ with PaO$_2$ in premature neonates without sepsis. In the case of proven sepsis, the LoA for tcPCO$_2$ with PaCO$_2$ widened remarkably. An equally interesting finding was the excellent agreement of tcPCO$_2$ with PaCO$_2$, despite sepsis in these premature neonates. Drift was negligible during tcPO$_2$ measurement and highly acceptable when measuring tcPCO$_2$ during standard care in premature neonates.

**Acknowledgement**

The authors would like to thank the nursing staff at Erasmus MC – Sophia Children’s Hospital for their support of this study.

**Statement of Ethics**

The Medical Ethical Board of Erasmus University Medical Center Rotterdam approved the study protocol (MEC-2015-514). A waiver of informed consent was given as all data were collected as part of regular clinical care.

**Conflict of Interest Statement**

The authors have no conflicts of interest to declare.

**Funding Sources**

This study was in part funded by SenTec AG.

**Author Contributions**

W.W., T.G.G., R.C.J.J., and I.K.M.R. designed and set up the study. W.W. and T.E. acquired the data. W.W., T.E., and N.H.G.-P. analyzed the data. W.W. and N.H.G.-P. wrote the manuscript. T.E. and N.H.G.-P. contributed equally to this work. All authors provided input on the final manuscript.

**References**

1. Rudiger M, Topfer K, Hammer H, Schmalisch G, Wauer RR. A survey of transcutaneous blood gas monitoring among European neonatal intensive care units. BMC Pediatr. 2005 Aug 10;5:30.
2. Ochiai M, Kurata H, Inoue H, Ichiyama M, Fujiiyoshi J, Watabe S, et al. Transcutaneous blood gas monitoring among neonatal intensive care units in Japan. Pediatr Int. 2020 Feb;62(2):169–74.
3. Lubbers DW. Theoretical basis of the transcutaneous blood gas measurements. Crit Care Med. 1981 Oct;9(10):721–33.
4. Lubbers DW. Theory and development of transcutaneous oxygen pressure measurement. Int Anesthesiol Clin. 1987 Fall;25(3):31–65.
5. Versmold HT, Holzmann M, Linderkamp O, Riegel KP. Skin oxygen permeability in premature infants. Pediatrics. 1978 Oct;62(4):488–91.
6. Versmold HT, Linderkamp O, Holzmann M, Strohhacker I, Riegel KP. Limits of tcPO$_2$ monitoring in sick neonates: relation to blood pressure, blood volume, peripheral blood flow and acid base status. Acta Anaesthesiol Scand Suppl. 1978;68:88–90.
7. Lofgren O, Jacobson L. The influence of different electrode temperatures on the recorded transcutaneous PO$_2$ level. Pediatrics. 1979 Dec;64(6):892–7.
8. Huch R, Lubbers DW, Huch A. Quantitative continuous measurement of partial oxygen pressure on the skin of adults and new-born babies. Pflugers Arch. 1972;337(3):185–98.
9. Hansen TN, Sonoda Y, McIlroy MB. Transfer of oxygen, nitrogen, and carbon dioxide through normal adult human skin. J Appl Physiol Respir Environ Exerc Physiol. 1980 Sep;49(3):438–43.
10. Wimberley PD, Grønlund Pedersen K, Olson J, Sigggaard-Andersen O. Transcutaneous carbon dioxide and oxygen tension measured at different temperatures in healthy adults. Clin Chem. 1985 Oct;31(10):1611–5.
11. Clark LC Jr. Monitor and control of blood and tissue oxygen tensions. ASAIO J. 1956;2(1):41–8.
12. Severinghaus JW. A combined transcutaneous PO$_2$-PCO$_2$ electrode with electrochemical HCO$_3$-stabilization. J Appl Physiol Respir Environ Exerc Physiol. 1981 Oct;51(4):1027–32.
13. Eberhard P, Mindt W, Jann F, Hammacher K. Continuous pO$_2$ monitoring in the neonate by skin electrodes. Med Biol Eng. 1975 May;13(3):436–42.
14. Severinghaus JW, Stafford M, Thunstrom AM. Estimation of skin metabolism and blood flow with tcPO$_2$ and tcPCO$_2$ electrodes by cuff occlusion of the circulation. Acta Anaesthesiol Scand Suppl. 1978;68:9–15.
15 Conway A, Tipton E, Liu WH, Conway Z, Soalheira K, Sutherland J, et al. Accuracy and precision of transcutaneous carbon dioxide monitoring: a systematic review and meta-analysis. Thorax. 2019 Feb;74(2):157–63.
16 van Weteringen W, Goos TG, van Essen T, Ellenberger C, Hayoz J, de Jonge RCJ, et al. Novel transcutaneous sensor combining optical tcPO2 and electrochemical tcPCO2 monitoring with reflectance pulse oximetry. Med Biol Eng Comput. 2020 Feb;58(2):239–47.
17 Opitz N, Lübbers DW. Theory and development of fluorescence-based optochemical oxygen optodes. Int Anesthesiol Clin. 1987 Fall;25(3):177–97.
18 Bland JM, Altman DG. Agreement between methods of measurement with multiple observations per individual. J Biopharm Stat. 2007;17(4):571–82.
19 Storre JH, Magnet FS, Dreher M, Windisch W. Transcutaneous monitoring as a replacement for arterial PCO2 monitoring during nocturnal non-invasive ventilation. Respir Med. 2011 Jan;105(1):143–50.
20 Aarrestad S, Tollefsen E, Kleiven AL, Qvarfort M, Janssens JP, Skjønsberg OH. Validity of transcutaneous PCO2 in monitoring chronic hypoventilation treated with non-invasive ventilation. Respir Med. 2016 Mar;112:112–8.
21 Palmisano BW, Severinghaus JW. Transcutaneous PO2 and PO2: a multicenter study of accuracy. J Clin Monit. 1990 Jul;6(3):189–95.
22 Sandberg KL, Brynjarsdottir H, Hjalmarsson O. Transcutaneous blood gas monitoring during neonatal intensive care. Acta Paediatr. 2011 May;100(5):676–9.
23 Lush CW, Kvietys PR. Microvascular dysfunction in sepsis. Microcirculation. 2000 Apr;7(2):83–101.
24 Wynn JL, Wong HR, Shanley TP, Bizzarro MJ, Saiman L, Polin RA. Time for a neonatal-specific consensus definition for sepsis. Pediatr Crit Care Med. 2014 Jul;15(6):523–8.
25 Falstie-Jensen N, Spaun E, Brochner-Mortensen J, Falstie-Jensen S. The influence of epidermal thickness on transcutaneous oxygen pressure measurements in normal persons. Scand J Clin Lab Invest. 1988 Oct;48(6):519–23.
26 Poets CF, Bassler D. Providing stability in oxygenation for preterm infants: is transcutaneous oxygen monitoring really better than pulse oximetry? Arch Dis Child Fetal Neonatal Ed. 2008 Sep;93(5):F330–1.
27 Quine D, Stenson BJ. Does the monitoring method influence stability of oxygenation in preterm infants? A randomised crossover study of saturation versus transcutaneous monitoring. Arch Dis Child Fetal Neonatal Ed. 2008 Sep;93(5):F347–50.
28 Poets CF. Noninvasive monitoring and assessment of oxygenation in infants. Clin Perinatol. 2019 Sep;46(3):417–33.